title: Responses of ferret lower esophageal sphincter to 5-hydroxytryptamine: pathways and receptor subtypes.
abstract: In urethananesthetized ferrets, basal lower esophageal sphincter pressure (LESP) was unaffected by the 5-hydroxytryptamine3 (5-HT3) receptor antagonist granisetron (0.5 mg/kg) or by greater splanchnic nerve section (GSX), but increased after bilateral vagotomy. Peripheral vagal nerve stimulation caused LES relaxation, often followed by a brief contraction and a prolonged inhibition of LESP. Close intra-arterial injection of 5-HT (5-100 micrograms) had a biphasic effect on LESP, with a brief drop followed by a prolonged increase. Granisetron (0.5 mg/kg i.v.) abolished the initial relaxation and revealed an earlier peak of excitation. This was not influenced by subsequent vagotomy and GSX. In a series of eight additional experiments (series 2), granisetron was given after vagotomy and GSX. In series 2, 5-HT-induced relaxation was unaffected by vagotomy but was significantly reduced after GSX and was further reduced after granisetron, indicating that 5-HT3 receptor mechanisms may lie on a sympathetic neural pathway. Vagotomy had no effect on the excitatory component. GSX had no effect on the amplitude of excitation, but reduced its latency. Granisetron had no further effect on excitation in series 2. In a separate series of 13 experiments (series 3), the excitatory component of the LES response to 5-HT was abolished by ketanserin (2.5 mg/kg i.v.) , after which only relaxation occurred. Both 5-HT2 and 5-HT3 antagonists in combination abolished all effects of 5-HT on LESP. Atropine (400 micrograms/kg i.v., n = 7) had no effect on 5-HT-induced LES responses.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Royal Adelaide Hospital, Australia.
authors.forename: L A
authors.initials: LA
authors.lastname: Blackshaw
authors.forename: V
authors.initials: V
authors.lastname: Nisyrios
authors.forename: J
authors.initials: J
authors.lastname: Dent
mesh_terms: D000818:Animals; D001285:Atropine / Q000494:pharmacology; D001643:Bridged Bicyclo Compounds / Q000494:pharmacology; D019086:Bridged Bicyclo Compounds, Heterocyclic; D004947:Esophagus / Q000187:drug effects / Q000294:innervation / Q000502:physiology*; D005260:Female; D005289:Ferrets; D017829:Granisetron / Q000494:pharmacology; D006145:Guanethidine / Q000494:pharmacology; D007211:Indoles / Q000494:pharmacology; D007650:Ketanserin / Q000494:pharmacology; D008297:Male; D009130:Muscle, Smooth / Q000187:drug effects / Q000294:innervation / Q000502:physiology*; D011985:Receptors, Serotonin / Q000502:physiology*; D012016:Reference Values; D012701:Serotonin / Q000494:pharmacology*; D012702:Serotonin Antagonists / Q000494:pharmacology; D013153:Splanchnic Nerves / Q000502:physiology; D013997:Time Factors; D014628:Vagotomy; D014630:Vagus Nerve / Q000502:physiology*
chemical_list: D001285:Atropine; D001643:Bridged Bicyclo Compounds; D019086:Bridged Bicyclo Compounds, Heterocyclic; D017829:Granisetron; D006145:Guanethidine; D007211:Indoles; D007650:Ketanserin; D011985:Receptors, Serotonin; D012701:Serotonin; D012702:Serotonin Antagonists; C075685:BRL 46470